Autopsy report · NCT00391586

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

“PI left institution.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 5 years 10 months before it stopped.
• 45 participants enrolled.
• Results were posted on the registry 3 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

New Mexico Cancer Research Alliance

Sponsor type

University, hospital or other

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Erlotinib; Platinum-based chemotherapy

Participants

45

Sites

5

Countries

United States

Trials that died the same way

• Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes
  “PI has left institution” (96% match in meaning)
• rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures
  “PI left the institution” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.